View Item 

Show simple item record

COVID‐19: The Uninvited Guest in the Intensive Care Unit — Implications for Pharmacotherapy
dc.contributor.authorStringer, Kathleen A.
dc.contributor.authorPuskarich, Michael A.
dc.contributor.authorKenes, Michael T.
dc.contributor.authorDickson, Robert P.
dc.date.accessioned2020-06-03T15:24:15Z
dc.date.availableWITHHELD_12_MONTHS
dc.date.available2020-06-03T15:24:15Z
dc.date.issued2020-05
dc.identifier.citationStringer, Kathleen A.; Puskarich, Michael A.; Kenes, Michael T.; Dickson, Robert P. (2020). "COVID‐19: The Uninvited Guest in the Intensive Care Unit — Implications for Pharmacotherapy." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 40(5): 382-386.
dc.identifier.issn0277-0008
dc.identifier.issn1875-9114
dc.identifier.urihttps://hdl.handle.net/2027.42/155543
dc.publisherWiley Periodicals, Inc.
dc.subject.otheracute respiratory distress syndrome
dc.subject.othercorona virus
dc.subject.otherCOVID‐19
dc.subject.otherintensive care unit
dc.titleCOVID‐19: The Uninvited Guest in the Intensive Care Unit — Implications for Pharmacotherapy
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/155543/1/phar2394.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/155543/2/phar2394_am.pdf
dc.identifier.doi10.1002/phar.2394
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
dc.identifier.citedreferenceSchrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 2020; 16 ( 3 ): 155 – 66.
dc.identifier.citedreferenceHolshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 10: 929 – 36.
dc.identifier.citedreferenceAgostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS‐5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 2018; 9: e00221‐18. https://doi.org/10.1128/mBio.00221‐18
dc.identifier.citedreferenceRussell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019‐nCoV lung injury. Lancet 2020; 395 ( 10223 ): 473 – 5.
dc.identifier.citedreferenceLansbury L, Rodrigo C, Leonardi‐Bee J, Nguyen‐Van‐Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev 2019; 2. https://doi.org/10.1002/14651858.CD010406.pub3
dc.identifier.citedreferenceSteinberg KP, Hudson LD, Goodman RB, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006; 16: 1671 – 84.
dc.identifier.citedreferenceVillar J, Ferrando C, Martinez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med 2020; 3: 267 – 76.
dc.identifier.citedreferenceTanaka T, Narazaki M, Kishimoto T. IL‐6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 2014; 6 ( 10 ): a016295.
dc.identifier.citedreferenceZhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study. Lancet 2020. https://doi.org/10.1016/S0140‐6736(20)30566‐3
dc.identifier.citedreferenceBime C, Casanova N, Oita RC, et al. Development of a biomarker mortality risk model in acute respiratory distress syndrome. Crit Care 2019; 23 ( 1 ): 410.
dc.identifier.citedreferenceDong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID‐19). Drug Discov Ther 2020; 14 ( 1 ): 58 – 60.
dc.identifier.citedreferenceLoutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon‐1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 2003; 290 ( 24 ): 3222 – 8.
dc.identifier.citedreferenceWang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019‐nCoV) in vitro. Cell Res 2020; 30 ( 3 ): 269 – 71.
dc.identifier.citedreferenceGao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID‐19 associated pneumonia in clinical studies. Biosci Trends 2020; 14 ( 1 ): 72 – 3.
dc.identifier.citedreferenceGautret P, Lagier J‐C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial. Int J Antimicrob Agents 2020. https://doi.org/10.1016/j.ijantimicag.2020.105949
dc.identifier.citedreferenceSchogler A, Kopf BS, Edwards MR, et al. Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. Eur Respir J 2015; 45 ( 2 ): 428 – 39.
dc.identifier.citedreferencePhillips A, Wainberg MA, Coates R, et al. Cyclosporine‐induced deterioration in patients with AIDS. CMAJ 1989; 12: 1456 – 60.
dc.identifier.citedreferenceAssociated Press. French AIDS patient, treated with cyclosporine, is dead. New York Times. November 12, 1985. C9.
dc.identifier.citedreferenceBayer R. The ethics of research on HIV/AIDS in community‐based settings. Aids 1990; 4 ( 12 ): 1287 – 8.
dc.identifier.citedreferenceByers VS, Levin AS, Waites LA, et al. A phase I/II study of trichosanthin treatment of HIV disease. Aids 1990; 4 ( 12 ): 1189 – 96.
dc.identifier.citedreferenceForce ADT, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012; 23. https://doi.org/10.1001/jama.2012.5669:2526‐33
dc.identifier.citedreferenceWu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID‐19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323 ( 13 ): 1239.
dc.identifier.citedreferenceGuan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020. https://doi.org/10.1056/NEJMoa2002032
dc.identifier.citedreferenceWorld Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Available from https://www.who.int/docs/default‐source/coronaviruse/clinical‐management‐of‐novel‐cov.pdf. Accessed March 20, 2020.
dc.identifier.citedreferenceArabi YM, Murthy S, Webb S. COVID‐19: a novel coronavirus and a novel challenge for critical care. Intensive Care Med 2020. https://doi.org/10.1007/s00134‐020‐05955‐1
dc.identifier.citedreferenceYang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS‐CoV‐2 pneumonia in Wuhan, China: a single‐centered, retrospective, observational study. Lancet Respir Med 2020. https://doi.org/10.1016/S2213‐2600(20)30079‐5
dc.identifier.citedreferenceHuang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 ( 10223 ): 497 – 506.
dc.identifier.citedreferenceChen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395 ( 10223 ): 507 – 13.
dc.identifier.citedreferenceShi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID‐19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 2020; 4. https://doi.org/10.1016/S1473‐3099(20)30086‐4:425‐34
dc.identifier.citedreferenceWang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020; 323 ( 11 ): 1061.
dc.identifier.citedreferenceMehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID‐19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395 ( 10229 ): 1033 – 4.
dc.identifier.citedreferenceFan E, Del Sorbo L, Goligher EC, et al. Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: mechanical ventilation in adult patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2017; 9: 1253 – 63.
dc.identifier.citedreferencePoston JT, Patel BK, Davis AM. Management of critically ill adults with COVID‐19. JAMA 2020. https://doi.org/10.1001/jama.2020.4914
dc.identifier.citedreferenceFerrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin‐converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin‐converting enzyme 2. Circulation 2005; 20: 2605 – 10.
dc.identifier.citedreferenceKuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus‐induced lung injury. Nat Med 2005; 8: 875 – 9.
dc.identifier.citedreferenceFedson DS, Opal SM, Rordam OM. Hiding in plain sight: an approach to treating patients with severe COVID‐19 infection. mBio 2020; 2. https://doi.org/10.1128/mBio.00398‐20
dc.identifier.citedreferenceHFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID‐19. Available from https://www.acc.org/latest‐in‐cardiology/articles/2020/03/17/08/59/hfsa‐acc‐aha‐statement‐addresses‐concerns‐re‐using‐raas‐antagonists‐in‐covid‐19. Accessed March 20, 2020.
dc.identifier.citedreferenceCao B, Wang Y, Wen D, et al. A trial of lopinavir‐ritonavir in adults hospitalized with severe Covid‐19. N Engl J Med 2020. https://doi.org/10.1056/NEJMoa2001282
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phar2394.pdf
Size:
86.09KB
Format:
PDF
View/Open
Name:
phar2394_am.pdf
Size:
273.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.